ResMed posts $1.4bn quarter as digital sleep health scales globally
ResMed, the San Diego-based sleep and respiratory health company, has reported first-quarter fiscal year 2027 revenue of $1.415 billion, a 6% rise year-on-year and 7% on a core constant currency basis, as demand for connected CPAP devices and AI-assisted software continues to expand across both the Americas and international markets. Non-GAAP diluted earnings per share climbed 14% to $2.91, while GAAP diluted EPS rose a sharper 23% to $2.92, partly reflecting a gain on the completed divestiture of its MatrixCare long-term-care software business.
The quarter illustrates a deliberate portfolio pivot. ResMed has shed MatrixCare, a residential care software platform serving skilled nursing and senior living facilities, to concentrate capital and management attention on what its chairman and CEO Mick Farrell calls "our digital health ecosystem." The proceeds from that sale, combined with $422 million in operating cash flow, funded more than $1 billion returned to shareholders through buybacks and dividends during the period, an unusually large capital return for a medtech company of ResMed's scale.
Device momentum meets software ambition
Sleep devices globally grew 9% in reported terms, with the Rest of World segment posting 12% revenue growth. Masks and accessories added 10% worldwide. The Americas segment led in absolute terms, generating $833 million, while Rest of World Sleep and Breathing Health reached $426 million. Residential Care Software, stripped of the MatrixCare contribution, grew 5% on a core constant currency basis; the retained Brightree and MEDIFOX DAN platforms actually grew 8% when measured on a like-for-like basis.
The company also announced a partnership with connected sleep-tech firm Eight Sleep, integrating ResMed's clinical sleep-data insights into Eight Sleep's smart mattress platform. That collaboration points to a convergence play between regulated medical devices and consumer wellness hardware, a boundary that the broader health-tech sector is navigating with increasing urgency as wearables and diagnostics blur.
The macro read: home care as infrastructure
The more significant strategic signal in this result is not the earnings beat itself but what it implies for the reconfiguration of healthcare delivery. ResMed's model, cloud-connected devices, AI-driven adherence software, remote patient monitoring, is, in effect, a distributed care infrastructure play. As hospital systems in the US and Europe face structural cost pressure and post-pandemic capacity constraints, payors and regulators are actively incentivising the shift of chronic-disease management into the home. Sleep apnea, affecting an estimated one billion people globally according to published epidemiological estimates, represents one of the largest under-diagnosed chronic conditions, and home-based CPAP therapy is among the most cost-effective interventions available.
For capital allocators tracking the convergence of medtech, digital health software, and consumer IoT, ResMed's trajectory illustrates a durable demand curve: device attach rates grow as diagnosis expands (the company's NASCAR driver partnership with Tyler Reddick, who was recently diagnosed with sleep apnea, is explicitly designed to widen the funnel), and software subscription revenues then compound on top. The company has maintained full-year FY2027 guidance of $5.75 to $5.85 billion in reported revenue and non-GAAP diluted EPS of $12.00 to $12.25.
The Eight Sleep partnership also raises a question that will matter to investors in adjacent spaces: as consumer wellness platforms accumulate richer biometric datasets, the competitive moat for regulated medical-device companies may increasingly rest on clinical-grade data provenance and payor reimbursement access, rather than on hardware alone. ResMed's ability to position its cloud platform as the authoritative layer between consumer sleep tech and clinical care will be a key variable to watch in FY2027.